CLOTIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLOTIC (CLOTIC).
Clotrimazole is an imidazole antifungal that inhibits ergosterol synthesis by inhibiting 14α-demethylase (CYP51), leading to disruption of fungal cell membrane integrity and increased permeability.
| Metabolism | Clotrimazole is primarily metabolized in the liver via oxidation and glucuronidation. Minor metabolism by CYP3A4; most of the drug is excreted as metabolites in bile and feces. |
| Excretion | Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as inactive conjugates. |
| Half-life | Terminal elimination half-life is 3.5 hours (range 2.5-4.5 h) in adults with normal renal function; extends to 6-8 hours in mild-moderate renal impairment. |
| Protein binding | 92-96% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent Vd is 0.5-0.7 L/kg, indicating distribution into total body water. |
| Bioavailability | Oral: 85-90% (first-pass metabolism minimal); Topical: 5-10% systemically absorbed. |
| Onset of Action | Oral: 30-60 minutes; IV: 5-10 minutes; Topical: 1-2 hours. |
| Duration of Action | Oral: 6-8 hours; IV: 6-8 hours; Topical: 12-24 hours depending on formulation. |
| Molecular Weight | 296.4 |
Topical: Apply a thin layer to affected areas 2-4 times daily. Duration limited to 2 weeks; maximum 50 g/week. Intralesional: 0.5-1 mL of 10 mg/mL solution injected into lesion weekly.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No specific dose adjustment required for topical or intralesional use. Systemic absorption is negligible; no GFR-based modifications. |
| Liver impairment | No dose adjustment necessary for topical or intralesional administration. No Child-Pugh based modifications. |
| Pediatric use | Topical: Apply sparingly once or twice daily. Limit to small areas; avoid prolonged use. Intralesional: Not recommended; alternative agents preferred. |
| Geriatric use | Use caution due to thinner skin; apply sparingly and limit duration. Monitor for skin atrophy and systemic effects. No specific dose reduction but avoid excessive use. |
| 1st trimester | Insufficient human data; animal studies show embryotoxicity at high doses. Avoid unless benefit outweighs risk. |
| 2nd trimester | Limited data; potential for fetal harm. Use only if clearly needed. |
| 3rd trimester | May cause premature closure of ductus arteriosus and oligohydramnios. Avoid in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for CLOTIC (CLOTIC).
| Placental transfer | Crosses placenta; detected in fetal tissues. Extent estimated 10-20% of maternal serum concentration. |
| Breastfeeding | Excreted into breast milk in low amounts. Not recommended due to potential adverse effects on infant, such as gastrointestinal bleeding or renal impairment. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to clotrimazole or any excipientPatients with hepatic impairment (severe)Avoid use in third trimester for systemic formulations
| Precautions | Hypersensitivity reactions (contact dermatitis, urticaria), Hepatic impairment (caution with systemic use, but topical application has minimal absorption), Avoid contact with eyes, Not for ophthalmic use, May cause local irritation or burning sensation, Immunocompromised patients may require longer treatment |
| Food/Dietary | No known food interactions. |
| Clinical Pearls |
Loading safety data…
| L4 |
| Teratogenic Risk | Clotrimazole (CLOTIC) is classified as FDA Pregnancy Category B. In animal studies, no teratogenic effects were observed at doses up to 100 mg/kg/day. However, human data are limited. First trimester exposure is not associated with increased risk of major birth defects. No specific fetal risks have been identified for second or third trimester use. |
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond standard prenatal care. If used for extended periods on large areas of skin, monitor for local irritation or hypersensitivity. |
| Fertility Effects | Clotrimazole has no known adverse effects on fertility. Animal studies showed no impairment of fertility at doses up to 100 mg/kg/day. |
| CLOTIC is a topical corticosteroid/antifungal combination typically used for otitis externa. Avoid use in perforated tympanic membrane. Limited to 7 days of therapy to prevent fungal overgrowth or resistance. Shake well before use. |
| Patient Advice | Use only in the ear, not for eye or oral use. · Shake the bottle well before each use. · Keep the bottle tip clean and do not touch the ear with the dropper. · Lie on your side with the affected ear up, instill drops, and remain for several minutes. · Complete the full course even if symptoms improve. · Do not use if you have a punctured eardrum or ear tube. · Report worsening pain, discharge, or hearing loss. |